Search Results - "Neyns, B"

Health-state utilities in long-term advanced melanoma survivors comparable with the general population.

Authors: Egeler, M. D. van de Poll-Franse, L. V. Tissier, R. et al.

Source: Quality of Life Research. Sep2023, Vol. 32 Issue 9, p2517-2525. 9p. 4 Charts.

Subjects: Melanoma, Quality-adjusted life years, Overall survival

441O A phase I clinical trial on the intracranial administration of autologous CD1c(BDCA-1)+ /CD141(BDCA-3)+ myeloid dendritic cells (myDC) in combination with ipilimumab (IPI) and nivolumab (NIVO) in patients with recurrent high-grade glioma (rHGG).

Authors: Neyns, B. Dirven, I. Lescrauwaet, L. et al.

Source: Annals of Oncology. 2024 Supplement 2, Vol. 35, pS406-S407. 2p.

Dose-dense temozolomide regimens: antitumor activity, toxicity, and immunomodulatory effects.

Authors: Neyns B Tosoni A Hwu WJ et al.

Source: Cancer (0008543X). 6/15/2010, Vol. 116 Issue 12, p2868-2877. 10p.

Stratified phase II trial of cetuximab in patients with recurrent high-grade glioma.

Authors: Neyns, B. Sadones, J. Joosens, E. et al.

Source: Annals of Oncology. Sep2009, Vol. 20 Issue 9, p1596-1603. 8p. 2 Diagrams, 4 Charts, 1 Graph.

342O Intracranial administration of CTLA-4 and PD-1 immune checkpoint blocking monoclonal antibodies in recurrent glioblastoma (rGB): A multi-cohort adaptive phase I clinical trial.

Authors: Neyns, B. Schwarze, J.K. Bertels, C. et al.

Source: Annals of Oncology. 2021 Supplement 5, Vol. 32, pS516-S517. 2p.

A novel triplet regimen with paclitaxel, carboplatin and gemcitabine (PACCAGE) as induction chemotherapy for locally advanced unresectable non small cell lung cancer (NSCLC)

Authors: Schallier, D. Neyns, B. Fontaine, C. et al.

Source: Lung Cancer (01695002). May2007, Vol. 56 Issue 2, p247-254. 8p.

Anti-CTLA-4 antibody-induced Guillain–Barré syndrome in a melanoma patient.

Authors: Wilgenhof, S. Neyns, B.

Source: Annals of Oncology. Apr2011, Vol. 22 Issue 4, p991-993. 3p. 1 Color Photograph.

Transduction of ovarian cancer cells: a recombinant adeno-associated viral vector compared to an adenoviral vector.

Authors: Vermeij, J Zeinoun, Z Neyns, B et al.

Source: British Journal of Cancer. 11/15/2001, Vol. 85 Issue 10, p1592. 8p.

Phase II trial of sunitinib malate in patients with temozolomide refractory recurrent high-grade glioma

Authors: Chaskis, C. Neyns, B. Dujardin, M. et al.

Source: Surgical Neurology. Nov2009, Vol. 72 Issue 5, p518-518. 1p.

P-570 Triplet induction chemotherapy followed by radiotherapy in inoperable stage III non small cell lung cancer (NSCLC). A phase II report

Authors: Schallier, D. Neyns, B. Vermeij, J. et al.

Source: Lung Cancer (01695002). Jul2005 Supplement 2, Vol. 49, pS268-S268. 1p.

Health-related quality of life of long-term advanced melanoma survivors treated with anti-CTLA-4 immune checkpoint inhibition compared to matched controls.

Authors: Boekhout, A. H. Rogiers, A. Jozwiak, K. et al.

Source: Acta Oncologica. Jan2021, Vol. 60 Issue 1, p69-77. 9p. 4 Charts, 1 Graph.

Nivolumab plus low-dose ipilimumab in previously treated patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: 4-year follow-up from CheckMate 142.

Authors: André, T. Lonardi, S. Wong, K.Y.M. et al.

Source: Annals of Oncology. Oct2022, Vol. 33 Issue 10, p1052-1060. 9p.

Antitumor activity of ipilimumab or BRAF ± MEK inhibition after pembrolizumab treatment in patients with advanced melanoma: analysis from KEYNOTE-006.

Authors: Long, G.V. Arance, A. Mortier, L. et al.

Source: Annals of Oncology. Feb2022, Vol. 33 Issue 2, p204-215. 12p.

Loading of dendritic cells for immunotherapy.

Authors: Nuffel, A. M. T. Benteyn, D. Wilgenhof, S. et al.

Source: ISBT Science Series. Jun2013, Vol. 8 Issue 1, p161-164. 4p. 1 Diagram.

Durable remission of inoperable liver metastasis from rectal cancer after hepatic arterial infusion of oxaliplatin and 5-fluorouracil in combination with intravenous cetuximab.

Authors: Van Bael, K. Aerts, M. de Ridder, M. et al.

Source: Current Oncology. Oct2011, Vol. 18 Issue 5, pe256-e260. 4p. 2 Black and White Photographs, 1 Map.

2556P The effectiveness of integrative neuro-cognitive remediation therapy (INCRT) for cancer survivors with cognitive problems: A prospective cohort study.

Authors: Vanlaer, N. Decabooter, L. Van Eycken, S. et al.

Source: Annals of Oncology. 2025 Supplement 2, Vol. 36, pS1377-S1377. 1p.

1643P A phase II clinical trial of regorafenib (REGO) combined with BRAF-/MEK-inhibitors in advanced pretreated BRAFV600-mutant (mut) melanoma (RegoMel).

Authors: Dirven, I. Bertels, C. Vounckx, M. et al.

Source: Annals of Oncology. 2025 Supplement 2, Vol. 36, pS975-S975. 1p.

Delayed immune-related adverse events with anti-PD-1-based immunotherapy in melanoma.

Authors: Owen, C.N. Bai, X. Quah, T. et al.

Source: Annals of Oncology. Jul2021, Vol. 32 Issue 7, p917-925. 9p.

The predictive and prognostic significance of cell‐free DNA concentration in melanoma.

Authors: Váraljai, R. Elouali, S. Lueong, S.S. et al.

Source: Journal of the European Academy of Dermatology & Venereology. Feb2021, Vol. 35 Issue 2, p387-395. 9p.

1132P Regorafenib in Caucasian patients with pretreated advanced KIT-mutant melanoma: A dual center case series.

Authors: Dirven, I. De Vita, E. Vounckx, M. et al.

Source: Annals of Oncology. 2024 Supplement 2, Vol. 35, pS743-S744. 2p.